Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease

Department of Endocrinology, Rigshospitalet, National University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. ufeldt@rh.dk

OBJECTIVE: To compare baseline characteristics in adult patients with growth hormone (GH) deficiency (GHD) who had previously been treated for Cushing's disease or acromegaly with data from patients with GHD of other aetiologies. To study the effects of GH therapy in those patients who had completed at least 6 months of GH replacement. DESIGN: Data from a large outcomes research database (KIMS (Pharmacia International Metabolic Database)). METHODS: 135 patients were identified with previous Cushing's disease, 40 had had acromegaly, and 1392 had GHD of other aetiologies. The number of additional hormone deficiencies, and the mean age of the patients were similar in the three groups. Similar proportions of patients in each group were treated using surgery, but radiotherapy was used more often in patients with acromegaly than those with other diagnoses. RESULTS: At baseline, the prevalence of diabetes mellitus and hypertension were significantly higher in the group treated for Cushing's disease, and the prevalence of stroke was significantly higher in the group treated for acromegaly. The incidence of coronary heart disease and claudication were similar in all three groups. Patients treated for Cushing's disease had lower bone mineral density and suffered fractures more often than other GHD adults. Body mass index, waist-hip ratio, serum concentrations of lipids and standard deviation scores of serum concentrations of insulin-like-growth factor-I were similar in the three groups. The dose of GH administered was comparable in the three groups and the effects of GH replacement on waist circumference, blood pressure and quality of life were also similar across the groups. The numbers and types of adverse events reported were not different between the groups. CONCLUSIONS: These data suggest that the characteristics of patients in these diagnostic groups depend on the primary disease which resulted in GHD, and that the clinical expression of GHD does not differ between the groups. Patients with previous hypercortisolism showed more long-term effects of their disease, such as diabetes mellitus, hypertension and fractures. A benefit from GH replacement was evident in patients previously treated for acromegaly and Cushing's disease particularly in relation to quality of life.

This article has been cited by other articles:

				L.-L. Norrman, G. Johannsson, K. S. Sunnerhagen, and J. Svensson Baseline Characteristics and the Effects of Two Years of Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency Previously Treated for Acromegaly J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2531 - 2538. [Abstract] [Full Text] [PDF]

				S M Webb, X Badia, M J Barahona, A Colao, C J Strasburger, A Tabarin, M O van Aken, R Pivonello, G Stalla, S W J Lamberts, et al. Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire Eur. J. Endocrinol., May 1, 2008; 158(5): 623 - 630. [Abstract] [Full Text] [PDF]

				C. Hoybye, P. Jonsson, J. P Monson, M. Koltowska-Haggstrom, V. Hana, M. Geffner, and R. Abs Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency Eur. J. Endocrinol., November 1, 2007; 157(5): 589 - 596. [Abstract] [Full Text] [PDF]

				G. Brabant, A. Krogh Rasmussen, B. M. K. Biller, M. Buchfelder, U. Feldt-Rasmussen, K. Forssmann, B. Jonsson, M. Koltowska-Haggstrom, D. Maiter, B. Saller, et al. Clinical Implications of Residual Growth Hormone (GH) Response to Provocative Testing in Adults with Severe GH Deficiency J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2604 - 2609. [Abstract] [Full Text] [PDF]

				A. A van der Klaauw, N. R Biermasz, E. J M Feskens, M. B Bos, J. W A Smit, F. Roelfsema, E. P M Corssmit, H. Pijl, J. A Romijn, and A. M Pereira The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH Eur. J. Endocrinol., April 1, 2007; 156(4): 455 - 462. [Abstract] [Full Text] [PDF]

				F. Pecori Giraldi, M. Andrioli, L. De Marinis, A. Bianchi, A. Giampietro, M. De Martin, E. Sacco, M. Scacchi, A. Pontecorvi, and F. Cavagnini Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease Eur. J. Endocrinol., February 1, 2007; 156(2): 233 - 239. [Abstract] [Full Text] [PDF]

				M. O. van Aken, A. M. Pereira, N. R. Biermasz, S. W. van Thiel, H. C. Hoftijzer, J. W. A. Smit, F. Roelfsema, S. W. J. Lamberts, and J. A. Romijn Quality of Life in Patients after Long-Term Biochemical Cure of Cushing's Disease J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3279 - 3286. [Abstract] [Full Text] [PDF]

				N. R Biermasz, N. A T Hamdy, A. M Pereira, J. A Romijn, and F. Roelfsema Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly Eur. J. Endocrinol., January 1, 2005; 152(1): 53 - 60. [Abstract] [Full Text] [PDF]

				G. Arnaldi, A. Angeli, A. B. Atkinson, X. Bertagna, F. Cavagnini, G. P. Chrousos, G. A. Fava, J. W. Findling, R. C. Gaillard, A. B. Grossman, et al. Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5593 - 5602. [Abstract] [Full Text] [PDF]